Notable Labs logo

Notable Labs(OTC) NTBL

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2023)-100%
5 YearN/A
1 Year+0%
1 Month+0%
N/A
Notable Labs last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-09
Notable Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-09-29
1 month+0%USD 0.002026-09-01
3 month+0%USD 0.002026-06-30
Year to date-99%USD 0.002025-12-31
1 year+0%USD 0.002025-10-09
Since inception-100%USD 4.452023-10-17

Notable Labs Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$3.00K

Net Income (TTM)

-$12.50M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 12, 2024

NTBL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Notable Labs

Notable Labs, Ltd. is a clinical-stage therapeutic platform company focused on developing predictive, personalized treatments for cancer patients. Utilizing its proprietary Predictive Precision Medicines Platform (PPMP), the company aims to enhance the clinical development process by identifying patients likely to respond favorably to specific therapies.

Products and Services
  • Predictive Precision Medicines Platform (PPMP) for personalized cancer treatment
  • Volasertib, a PLK-1 inhibitor targeting acute myeloid leukemia
  • Fosciclopirox, a prodrug aimed at treating acute myeloid leukemia
Growth Outlook
  • Recent quarterly revenue increased to $2,000, reflecting a positive trend
  • Strong cash position with $4.09 million available as of June 30, 2024
  • Focus on accelerating clinical trials to enhance patient outcomes and market entry
Financial Highlights
  • Trailing twelve months (TTM) revenue of $3,000, indicating growth potential
  • Operating expenses for Q2 2024 totaled $5.31 million, reflecting ongoing investment in R&D
  • Current ratio of 5.65 suggests strong liquidity and financial stability
Notable Labs, Ltd. operates in the biotechnology sector, emphasizing innovative solutions for cancer treatment. The company's PPMP allows for virtual testing of therapies, which can significantly reduce the time required for clinical trials. The development pipeline includes promising candidates like Volasertib and Fosciclopirox, which target critical areas in cancer treatment. The growth outlook appears favorable, with recent revenue increases and a solid cash position. The company is well-positioned to leverage its technology and expertise to meet the needs of patients and healthcare providers. Financially, Notable Labs has maintained a strong liquidity position, which is crucial for funding ongoing research and development efforts. Overall, the company represents a compelling opportunity in the biotechnology landscape, particularly for investors interested in innovative cancer therapies.
AI Generated • Sep 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

7

CEO

Thomas A. Bock, MD, MBA

Website

www.notablelabs.com

Headquarters

Or-Yehuda, 60376, IL

NTBL Financials

Key Financial Metrics (TTM)

Gross Margin

36.45%

Operating Margin

-4728.06%

Net Income Margin

-3633.55%

Return on Equity

-59.97%

Return on Capital

-85.40%

Return on Assets

-57.64%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$63.00K

Operating Income

-$12.84M

EBITDA

-$17.47M

Operating Cash Flow

-$11.26M

Capital Expenditure

-$45.00K

Free Cash Flow

-$11.30M

Cash & ST Invst.

$4.09M

Total Debt

$1.80M

Notable Labs Performance Analysis

Notable Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 768,000N/A
20222022-12-31USD 658,000-14.3%
Notable Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-31N/A
Q22023-06-30N/A
Q12024-03-31N/A
Q22024-06-30100.0%
Notable Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -15.78N/A
20222022-12-31USD -14.58-7.6%
Notable Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12023-03-3127.4%
Q22023-06-3067.2%
Q12024-03-31N/A
Q22024-06-30-31.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

$2.00K

N/A

Gross Profit

-$62.00K

N/A

Gross Margin

-31.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

16

N/A

Net Income

-$5.22M

-59.5%

EBITDA

-$5.32M

-63.6%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

$4.09M

-80.6%

Total Debt

$1.80M

+218.3%

Accounts Receivable

$184.00K

+80.4%

Inventory

$0.00

N/A

Long Term Debt

$1.25M

N/A

Short Term Debt

$546.00K

-3.2%

Return on Assets

-57.64%

N/A

Return on Invested Capital

-87.23%

N/A

Free Cash Flow

-$3.72M

+40.9%

Operating Cash Flow

-$3.71M

+41.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PTNPalatin Technologies, Inc.
$6.49-12.53%
NOVNNovan, Inc.
$0.09-24.84%
BPTSBiophytis S.A.
$8.22-13.47%
PLXPPLx Pharma Inc.
$0.09+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
CCCCCC Intelligent Solutions
$7.63-0.13%
INTCIntel
$95.37-2.80%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$107.35-2.89%
CRWVCoreWeave
$69.69+5.94%

Questions About NTBL

What is the current price of Notable Labs?

Notable Labs is trading at N/A per share.

What is the 52-week range for Notable Labs?

Over the past 52 weeks, Notable Labs has traded between N/A and N/A.

How much debt does Notable Labs have?

As of the most recent reporting period, Notable Labs reported total debt of $564.00K.

How much cash does Notable Labs have on hand?

Notable Labs reported $18.03M in cash and cash equivalents in its most recent financial results.

What is Notable Labs’s dividend yield?

Notable Labs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services